To read this content please select one of the options below:

Alpha-Stim AID cranial electrotherapy stimulation (CES) anxiety treatment: anxiety, depression and health-related quality-of-life outcomes in primary health-care social prescribing services

Chris Griffiths (Department of Research and Innovation, Northamptonshire Healthcare NHS Foundation Trust, Lichfield, UK)
Ksenija da Silva (Centre for Healthcare and Communities, Coventry University, Coventry, UK)
Harmony Jiang (Department of Research and Innovation, Northamptonshire Healthcare NHS Foundation Trust, Lichfield, UK)
Kate Walker (Department of Research and Innovation, Northamptonshire Healthcare NHS Foundation Trust, Northampton, UK)
David Smart (General Practice Alliance, Northampton, UK)
Azhar Zafar (General Practice Alliance, Northampton, UK and The University of Buckingham Medical School, Buckingham, UK)
Sarah Deeks (General Practice Alliance, Northampton, UK)
Sinead Galvin (General Practice Alliance, Northampton, UK)
Taz Shah (General Practice Alliance, Northampton, UK)

Mental Health Review Journal

ISSN: 1361-9322

Article publication date: 25 May 2023

Issue publication date: 9 November 2023

48

Abstract

Purpose

This study aims to evaluate the effect of Alpha-Stim Anxiety, Insomnia and Depression (AID) cranial electrotherapy stimulation (CES) on anxiety, depression and health-related quality of life for primary care social prescribing service patients with anxiety symptoms.

Design/methodology/approach

Open-label patient cohort design with no control group. A total of 33 adult patients (average age 42 years) completed six weeks of Alpha-Stim AID use. Pre- and post-intervention assessment with participant self-report measures: Patient Health Questionnaire (PHQ-9), Generalised Anxiety Disorder (GAD-7) and European Quality of Life Five Dimension (EQ-5D-5L).

Findings

Reliable improvement and remission rates, respectively, were 53.39% and 33.3% for GAD-7; 46.7% and 29.5% for PHQ-9. There was a significant improvement in GAD-7 and PHQ-9 with large effect sizes. EQ-5D-5L results showed significant improvements in health-related quality of life. Perceived quality of life increased by 0.17 on the health index score, with the intervention adding 1.68 quality-adjusted life years (QALYs).

Practical implications

Alpha-Stim AID can be delivered through a primary health-care social prescribing service and most patients will use as prescribed and complete treatment course. Alpha-Stim AID CES may be an effective anxiety and depression treatment for people with anxiety symptoms. The widespread roll-out of Alpha-Stim AID in health-care systems should be considered.

Originality/value

To the best of the authors’ knowledge, this is the first study to respond to the UK’s National Institute for Health and Care (NICE) request for the collection of real-world data to understand better Alpha-Stim AID in relation to people’s treatment uptake, response rates and treatment completion rates (NICE, 2021).

Keywords

Acknowledgements

East Midlands Academic Health Science Network.

Innovation award.

Funding: Funding was provided by East Midlands Academic Health Science Network (EMAHSN).

Citation

Griffiths, C., da Silva, K., Jiang, H., Walker, K., Smart, D., Zafar, A., Deeks, S., Galvin, S. and Shah, T. (2023), "Alpha-Stim AID cranial electrotherapy stimulation (CES) anxiety treatment: anxiety, depression and health-related quality-of-life outcomes in primary health-care social prescribing services", Mental Health Review Journal, Vol. 28 No. 4, pp. 337-349. https://doi.org/10.1108/MHRJ-11-2022-0068

Publisher

:

Emerald Publishing Limited

Copyright © 2023, Emerald Publishing Limited

Related articles